Ticker
ADAG

Price
1.43
Stock movement up
+0.05 (3.62%)
Company name
Adagene Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
62.63M
Ent value
-78.81M
Price/Sales
160.00
Price/Book
0.40
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-91.53%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADAG does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales160.00
Price to Book0.40
EV to Sales-201.36

FINANCIALS

Per share

Loading...
Per share data
Current share count43.79M
EPS (TTM)-0.23
FCF per share (TTM)-0.16

Income statement

Loading...
Income statement data
Revenue (TTM)391.41K
Gross profit (TTM)0.00
Operating income (TTM)-12.45M
Net income (TTM)-12.77M
EPS (TTM)-0.23
EPS (1y forward)-2.44

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-3179.59%
Profit margin (TTM)-3261.99%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash174.39M
Net receivables7.51M
Total current assets185.95M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets189.51M
Accounts payable3.32M
Short/Current long term debt7.49M
Total current liabilities29.82M
Total liabilities32.95M
Shareholder's equity156.56M
Net tangible assets156.56M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-8.54M
Capital expenditures (TTM)360.75K
Free cash flow (TTM)-8.90M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-8.16%
Return on Assets-6.74%
Return on Invested Capital-7.78%
Cash Return on Invested Capital-5.43%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.40
Daily high1.46
Daily low1.37
Daily Volume51K
All-time high29.60
1y analyst estimate24.69
Beta-
EPS (TTM)-0.23
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADAGS&P500
Current price drop from All-time high-95.17%-13.41%
Highest price drop-95.81%-56.47%
Date of highest drop17 Aug 20229 Mar 2009
Avg drop from high-64.99%-11.38%
Avg time to new high195 days12 days
Max time to new high387 days1805 days
COMPANY DETAILS
ADAG (Adagene Inc) company logo
Marketcap
62.63M
Marketcap category
Small-cap
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Employees
259
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report re...
September 10, 2022
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be pre...
August 30, 2022
SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today an...
June 29, 2022
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the potential best-in-c...
May 27, 2022
SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ann...
May 12, 2022
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
May 2, 2022
- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings planned for two new product candidates in 2022, includi...
April 8, 2022
In this article, we discuss the 10 best non-tech Chinese stocks to buy now. If you want to read about some more non-tech Chinese stocks, go directly to 5 Best Non-Tech Chinese Stocks to Buy Now. Chine...
April 3, 2022
- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater effic...
March 31, 2022
The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
March 17, 2022
Next page